BlackRock, Inc. Increases Stake in Edwards Lifesciences Corp

BlackRock, Inc. has filed a Schedule 13G/A amendment, disclosing an increased ownership of 7.5% in Edwards Lifesciences Corp. The filing indicates that BlackRock now beneficially owns 44,267,376 shares of the company's common stock, up from 28,356,383 shares previously. The value of these shares has also increased significantly, from $18,475,208,631.88 to $51,401,506,316.16, representing a 178.22% increase. The filing also notes that various persons have the right to receive dividends or direct the sale of these shares, but no single person's interest exceeds 5% of the total outstanding shares. The amendment was signed by Spencer Fleming, Managing Director of BlackRock, Inc.